Trial Profile
A Phase IIB, Multi-Center, Dose-Parallel, Randomized, Double-Blind, Monotherapy and Placebo-Controlled Safety and Efficacy Study of Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Nov 2016
Price :
$35
*
At a glance
- Drugs Bupropion/zonisamide (Primary) ; Bupropion; Zonisamide
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Orexigen Therapeutics [CEASED]
- 11 Jul 2010 Results presented at the 11th International Congress on Obesity.
- 28 Jun 2010 Results were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA 2010).
- 21 Jun 2010 Data will be presented at the American Diabetes Association 70th Scientific Sessions (Abstract 1841-P), according to an Orexigen Therapeutics media release.